Open access
Oct 2026
Development and study of a novel anti-HER2 therapeutic conjugate based on DARPin G3
Introduction. Overexpression of human epidermal growth factor receptor 2 (HER2) is a critical driver of malignancy in multiple solid tumors, underscoring the demand for innovative targeted therapeutics. Protein–drug conjugates offer selective delivery of highly potent cytotoxic payloads directly to tumor cells. Desi...
A. Prach, M. Larkina, S. Krivoshchekov et al.
· Drug development & regis... · 0 citations